Phase Ib Study of MK-3475 in Subjects With Advanced Melanoma

Trial Profile

Phase Ib Study of MK-3475 in Subjects With Advanced Melanoma

Completed
Phase of Trial: Phase I

Latest Information Update: 15 May 2017

At a glance

  • Drugs Pembrolizumab (Primary)
  • Indications Malignant melanoma
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms KEYNOTE-041
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 05 Apr 2017 Status changed from active, no longer recruiting to completed.
    • 25 Nov 2016 Planned End Date changed from 1 Nov 2016 to 1 Jun 2016.
    • 11 Jul 2016 Planned End Date changed from 1 Mar 2017 to 1 Nov 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top